YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14
J-M Huang(Harbin Medical University), Qiang Wang(Cedars-Sinai Medical Center), Beth Y. Karlan(University of California, Los Angeles), Hongtao Zhang(Chinese Academy of Sciences), Toru Kumagai(University of Pennsylvania), Emi Suzuki(Kobe University), Mark I. Greene(University of Pennsylvania), Takako Mizuno(Cedars-Sinai Medical Center), Alan Berezov, Izumi Nagatomo(Osaka City University)
Cited by 151
Related Papers
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.1k
National Survey of Drug-Resistant Tuberculosis in China
|New England Journal of Medicine|2012|649
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2019|617
ErbB receptors: from oncogenes to targeted cancer therapies
|Journal of Clinical Investigation|2007|578